Publicaciones (27) Publicaciones en las que ha participado algún/a investigador/a

2012

  1. Advances in cutaneous melanoma

    Clinical and Translational Oncology, Vol. 14, Núm. 5, pp. 325-332

  2. Adverse events risk associated with bevacizumab addition to breast cancer chemotherapy: A meta-analysis

    Annals of Oncology, Vol. 23, Núm. 5, pp. 1130-1137

  3. An innovative tool for intraoperative electron beam radiotherapy simulation and planning: Description and initial evaluation by radiation oncologists

    International Journal of Radiation Oncology Biology Physics, Vol. 83, Núm. 2

  4. CD8 T cell priming in the presence of IFN-α renders CTLs with improved responsiveness to homeostatic cytokines and recall antigens: important traits for adoptive T cell therapy

    Journal of Immunology, Vol. 189, Núm. 7, pp. 3299-3310

  5. Cardiotrophin-1 determines liver engraftment of syngenic colon carcinoma cells through an immune system-mediated mechanism

    OncoImmunology, Vol. 1, Núm. 9, pp. 1527-1536

  6. Comparison of limited-volume perioperative high-dose-rate brachytherapy and wide-field external irradiation in resected head and neck cancer

    Head and Neck, Vol. 34, Núm. 8, pp. 1081-1088

  7. Dabrafenib in BRAF-mutated metastatic melanoma: A multicentre, open-label, phase 3 randomised controlled trial

    The Lancet, Vol. 380, Núm. 9839, pp. 358-365

  8. Erlotinib and chemoradiation in patients with surgically resected locally advanced squamous cell carcinoma of the head and neck: A GICOR phase I trial

    Annals of Oncology, Vol. 23, Núm. 4, pp. 1005-1009

  9. External-beam radiation therapy and high-dose rate brachytherapy combined with long-term androgen deprivation therapy in high and very high prostate cancer: Preliminary data on clinical outcome

    International Journal of Radiation Oncology Biology Physics, Vol. 82, Núm. 3

  10. Family history record and hereditary cancer risk perception according to national cancer institute criteria in a Spanish medical oncology service: A retrospective study

    Oncology, Vol. 82, Núm. 1, pp. 30-34

  11. Fc gamma receptor polymorphisms as predictive markers of Cetuximab efficacy in epidermal growth factor receptor downstream-mutated metastatic colorectal cancer

    European Journal of Cancer, Vol. 48, Núm. 12, pp. 1774-1780

  12. Four-week neoadjuvant intensity-modulated radiation therapy with concurrent capecitabine and oxaliplatin in locally advanced rectal cancer patients: A validation phase II trial

    International Journal of Radiation Oncology Biology Physics, Vol. 83, Núm. 2, pp. 587-593

  13. Identification of colorectal cancer metastasis markers by an angiogenesis-related cytokine-antibody array

    World Journal of Gastroenterology, Vol. 18, Núm. 7, pp. 637-645

  14. Identification of predictive circulating biomarkers of bevacizumab- containing regimen efficacy in pre-treated metastatic colorectal cancer patients

    British Journal of Cancer, Vol. 107, Núm. 2, pp. 287-290

  15. Immunotherapeutic synergy between anti-CD137 mAb and intratumoral administration of a cytopathic semliki forest virus encoding IL-12

    Molecular Therapy, Vol. 20, Núm. 9, pp. 1664-1675

  16. Long-term results of 1-week intravaginal high-dose-rate brachytherapy alone for endometrial cancer

    Brachytherapy, Vol. 11, Núm. 2, pp. 119-124

  17. Novel antiangiogenic therapies against advanced hepatocellular carcinoma (HCC)

    Clinical and Translational Oncology, Vol. 14, Núm. 8, pp. 564-574

  18. Ovarian low-grade serous carcinoma: A comprehensive update

    Gynecologic Oncology, Vol. 126, Núm. 2, pp. 279-285

  19. Pathological vertebral fracture after stereotactic body radiation therapy for lung metastases. Case report and literature review

    Radiation Oncology, Vol. 7, Núm. 1

  20. Predictive factors for response to treatment in patients with advanced renal cell carcinoma

    Investigational New Drugs, Vol. 30, Núm. 6, pp. 2443-2449